There are 2789 resources available
540P - Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4
Presenter: David Hong
Session: ePoster Display
425P - Cetuximab could be administered once every two weeks instead of once weekly
Presenter: sarah Lobet
Session: ePoster Display
426P - Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care
Presenter: Augusto Valdivia
Session: ePoster Display
427P - Real world data of trifluridine/tipiracil in refractory mCRC: A multicenter experience at four GEODA Spanish hospitals
Presenter: Julia Martinez Perez
Session: ePoster Display
428P - Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer
Presenter: Hong Qiu
Session: ePoster Display
Resources:
Abstract
430P - Learning from FOCUS4: A molecularly stratified adaptive trial platform in metastatic colorectal cancer
Presenter: Janet Graham
Session: ePoster Display
Resources:
Abstract
475P - A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302)
Presenter: Jordan Berlin
Session: ePoster Display
476P - Open-label phase I/II study evaluating the tolerability and antitumor activity of selinexor (SEL) and pembrolizumab (pembro) in colorectal cancer (CRC)
Presenter: Talia Shentzer Kutiel
Session: ePoster Display
477P - Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Heinz Josef Lenz
Session: ePoster Display